Shingles,
commonly known as herpes zoster, is a virus that attacks the brain's cranial
nerves. It's caused by the varicella zoster virus, which is also responsible
for chicken pox. Because the virus can remain dormant in the human body for
several years, everyone who has had chicken pox before is at risk of acquiring
shingles. According to the Centers for Disease Control and Prevention (CDC),
one million cases of shingles were reported in the United States in 2018.
Furthermore, the CDC estimates that one out of every three persons in the
United States will have shingles at some point in their lives. The risk of
shingles increases with age, with the majority of occurrences occurring in
adults over the age of 40. This is primarily due to a weakened immune system as
a result of increased stress and insufficient consumption of vital nutrients to
maintain immunity.
Skin rashes,
nerve discomfort, eyesight loss, cold, upset stomach, muscle weakness, skin
infection, and scarring are some of the symptoms. Antiviral medications such as
acyclovir, valacyclovir, and famciclovir are used to treat shingles. These
medications aid in reducing the length and intensity of the sickness.
Furthermore, analgesics may aid in pain relief.
Global Shingles Vaccine Market
Dynamics
Merck &
Co., Inc. licenced the Zostavax vaccine in 2006, and it is an effective
shingles vaccine. The vaccine is indicated for those who are 50 years old or
older. The Zostavax vaccination was found to be 64% effective in adults aged 60
to 69 years old in clinical studies. As people get older, their effectiveness
decreases, dropping to 41% for those aged 70–79 and 18% for those aged 80 and
up. In February 2016, the vaccine was introduced in India at half the price of
the US market. In 2015, Zostavax was the sole shingles
vaccine market, with sales of $749 million.
Global Shingles Vaccine Market
Regional Analysis
Between 2016
and 2024, North America and Europe are estimated to account for the majority of
the market. The market in North America is likely to rise because to rising
demand in the United States, while the market in Europe is expected to grow due
to increased therapeutic demand from the European Union.
Over the
projected period, the Asia Pacific shingles vaccine market is expected to
develop at the fastest rate. In the region, particularly in China and India,
there is a large potential market that has to be exploited. Companies would
benefit from active marketing and differential pricing to strengthen their
market position in Asia Pacific.
Global Shingles Vaccine Market
Opportunity
Shingles is
becoming more common over the world, owing to a growing senior population.
However, in emerging nations with insufficient insurance coverage, the high
expense of vaccines is reducing vaccination. The reduction in postherpetic
neuralgia caused by the shingles vaccine is a major source of worry among
healthcare professionals. Because of the vaccine's effect in reducing the
likelihood of developing herpes zoster, Zostavax has been successful in
reducing postherpetic neuralgia to some extent. Shingrix with better results
would be a windfall to the lucrative worldwide shingles vaccination market.
Comments
Post a Comment